Quince Therapeutics (QNCX) Stock Forecast & Price Target

$1.71 +0.11 (+6.88%)

As of 11:33 AM Eastern

Quince Therapeutics - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 10 Analyst Ratings

Sell
0

Hold
0

Buy
10

Based on 10 Wall Street analysts who have issued ratings for Quince Therapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 10 analysts, 7 have given a buy rating, and 3 have given a strong buy rating for QNCX.

Consensus Price Target

$8.14
376.19% Upside

According to the 10 analysts' twelve-month price targets for Quince Therapeutics, the average price target is $8.14. The highest price target for QNCX is $11.00, while the lowest price target for QNCX is $4.00. The average price target represents a forecasted upside of 376.19% from the current price of $1.71.

Get the Latest News and Ratings for QNCX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Quince Therapeutics and its competitors.

QNCX Analyst Ratings Over Time

Type	Current Forecast 8/12/24 to 8/12/25	1 Month Ago 7/13/24 to 7/13/25	3 Months Ago 5/14/24 to 5/14/25	1 Year Ago 8/13/23 to 8/12/24
Strong Buy	3 Strong Buy rating(s)	2 Strong Buy rating(s)	2 Strong Buy rating(s)	N/A
Buy	7 Buy rating(s)	5 Buy rating(s)	5 Buy rating(s)	N/A
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	N/A
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	N/A
Consensus Price Target	$8.14	$8.00	$8.00	N/A
Forecasted Upside	376.19% Upside	339.56% Upside	850.80% Upside	N/A
Consensus Rating	Buy	Buy	Buy	N/A

QNCX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

QNCX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Quince Therapeutics Stock vs. The Competition

Type	Quince Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	3.30	2.81	2.53
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	417.86% Upside	12,473.50% Upside	14.29% Upside
News Sentiment Rating	Positive News See Recent QNCX News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
8/12/2025	JMP Securities 3 of 5 stars	Jonathan Wolleben Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Market Outperform ➝ Market Outperform	$9.00 ➝ $8.00	+409.55%
8/5/2025	Citigroup 3 of 5 stars		Initiated Coverage	Outperform
8/5/2025	Citizens Jmp 0 of 5 stars		Initiated Coverage	Strong-Buy	$9.00	+452.14%
7/17/2025	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Jason Kolbert Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00	+138.09%
3/24/2025	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Leland Gershell Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$10.00	+624.63%
12/18/2024	Brookline Capital Management Subscribe to MarketBeat All Access for the recommendation accuracy rating	K. Raja Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$9.00	+389.13%
11/7/2024	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Mccarthy Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$6.00	+310.96%
10/29/2024	RODMAN&RENSHAW Subscribe to MarketBeat All Access for the recommendation accuracy rating	E. Piros Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
10/29/2024	Rodman & Renshaw Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$11.00	+1,009.31%
10/22/2024	EF Hutton Acquisition Co. I Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Kolbert Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 11:34 AM ET.

QNCX Forecast - Frequently Asked Questions

: According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for Quince Therapeutics is $8.14, with a high forecast of $11.00 and a low forecast of $4.00.
: 10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Quince Therapeutics in the last twelve months. There are currently 7 buy ratings and 3 strong buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" QNCX shares.
: According to analysts, Quince Therapeutics's stock has a predicted upside of 376.19% based on their 12-month stock forecasts.
: Quince Therapeutics has been rated by research analysts at Citigroup, Citizens Jmp, D. Boral Capital, and JMP Securities in the past 90 days.
: Analysts like Quince Therapeutics more than other "medical" companies. The consensus rating for Quince Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how QNCX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NASDAQ:QNCX) was last updated on 8/12/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Quince Therapeutics (QNCX) Stock Forecast & Price Target